1. Home
  2. LGVN vs BDRX Comparison

LGVN vs BDRX Comparison

Compare LGVN & BDRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • LGVN
  • BDRX
  • Stock Information
  • Founded
  • LGVN 2014
  • BDRX 2000
  • Country
  • LGVN United States
  • BDRX United Kingdom
  • Employees
  • LGVN N/A
  • BDRX N/A
  • Industry
  • LGVN Medicinal Chemicals and Botanical Products
  • BDRX Biotechnology: Pharmaceutical Preparations
  • Sector
  • LGVN Health Care
  • BDRX Health Care
  • Exchange
  • LGVN Nasdaq
  • BDRX Nasdaq
  • Market Cap
  • LGVN 31.2M
  • BDRX 9.6M
  • IPO Year
  • LGVN 2021
  • BDRX N/A
  • Fundamental
  • Price
  • LGVN $2.91
  • BDRX $0.79
  • Analyst Decision
  • LGVN Strong Buy
  • BDRX Strong Buy
  • Analyst Count
  • LGVN 1
  • BDRX 1
  • Target Price
  • LGVN $12.00
  • BDRX $8.00
  • AVG Volume (30 Days)
  • LGVN 11.1M
  • BDRX 4.2M
  • Earning Date
  • LGVN 08-09-2024
  • BDRX 04-19-2024
  • Dividend Yield
  • LGVN N/A
  • BDRX N/A
  • EPS Growth
  • LGVN N/A
  • BDRX N/A
  • EPS
  • LGVN N/A
  • BDRX N/A
  • Revenue
  • LGVN $978,000.00
  • BDRX $482,278.00
  • Revenue This Year
  • LGVN $137.24
  • BDRX N/A
  • Revenue Next Year
  • LGVN $50.77
  • BDRX N/A
  • P/E Ratio
  • LGVN N/A
  • BDRX N/A
  • Revenue Growth
  • LGVN N/A
  • BDRX N/A
  • 52 Week Low
  • LGVN $0.77
  • BDRX $0.67
  • 52 Week High
  • LGVN $35.60
  • BDRX $9.64
  • Technical
  • Relative Strength Index (RSI)
  • LGVN 51.81
  • BDRX 41.76
  • Support Level
  • LGVN $2.90
  • BDRX $0.91
  • Resistance Level
  • LGVN $4.88
  • BDRX $1.20
  • Average True Range (ATR)
  • LGVN 0.70
  • BDRX 0.13
  • MACD
  • LGVN -0.04
  • BDRX -0.01
  • Stochastic Oscillator
  • LGVN 27.59
  • BDRX 8.57

About LGVN Longeveron Inc.

Longeveron Inc is a clinical-stage biotechnology company developing regenerative medicines to address unmet medical needs for specific aging-related and life-threatening conditions. Its investigational product is Lomecel-B an stem cell formulation sourced from the bone marrow of young, healthy adult donors and has potential mechanisms of action that can promote tissue repair and healing. The company currently has three pipeline indications: Hypoplastic Left Heart Syndrome (HLHS), Alzheimer's disease (AD) and Aging-related Frailty.

About BDRX Biodexa Pharmaceuticals plc American Depositary Shs

Biodexa Pharmaceuticals Plc is a drug delivery technology company focused on improving the bio-delivery and bio-distribution of medicines. The company combines approved and developed medications with its proprietary and innovative drug delivery technologies to provide compelling products that have the potential to powerfully impact the lives of patients.

Share on Social Networks: